Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
PURE Bioscience, Inc. specializes in the development of antimicrobial products, particularly its proprietary silver dihydrogen citrate (SDC) technology, which is utilized across various sectors including food safety, healthcare, and water treatment. The company's unique formulation offers a competitive edge due to its broad-spectrum efficacy and safety profile, positioning it favorably in the growing market for environmentally friendly disinfectants.
PURE generates revenue primarily through the sale of its antimicrobial products, leveraging its patented SDC technology. The company benefits from strong pricing power due to the unique efficacy of its products in comparison to traditional disinfectants, enabling it to capture a premium in various markets.
Regulatory approvals for new applications of SDC technology
Partnerships with major distributors in the food safety and healthcare sectors
Market adoption rates of antimicrobial products in response to health crises
Competitive advancements in alternative disinfectant technologies
Potential regulatory changes affecting the use of antimicrobial agents
Technological disruption from new disinfectant innovations
Emergence of lower-cost alternatives in the disinfectant market
Increased competition from established chemical manufacturers
Negative operating cash flow indicating potential liquidity issues
High operational losses impacting financial stability
moderate - The demand for antimicrobial products can be influenced by economic conditions, particularly in the food and healthcare sectors, which are sensitive to consumer spending and industrial activity.
Interest rates affect financing costs for operational expansions and R&D investments, potentially impacting growth if rates rise significantly.
minimal - The company operates with a negative debt/equity ratio, indicating a lack of reliance on external credit.
growth - Investors looking for exposure to innovative antimicrobial solutions in a growing market.
high - The company's historical volatility is significant due to fluctuating demand and operational challenges.